tiprankstipranks
Advertisement
Advertisement

CMVLF Stock Latest News

Cellectis highlights Allogene ALPHA3 trial data, potential milestone payments
The FlyCellectis highlights Allogene ALPHA3 trial data, potential milestone payments
16d ago
ALLO
CLLS
CMVLF Earnings this Week: How Will it Perform?
PremiumPre-Earnings
CMVLF Earnings this Week: How Will it Perform?
2M ago
Cellectis initiated with a Buy at Clear Street
PremiumThe Fly
Cellectis initiated with a Buy at Clear Street
4M ago
CLLS
Allogene Therapeutics says favorable result for Servier in Cellectis arbitration
PremiumThe Fly
Allogene Therapeutics says favorable result for Servier in Cellectis arbitration
4M ago
ALLO
CLLS
Cellectis announces arbitral decision in dispute with Servier
PremiumThe Fly
Cellectis announces arbitral decision in dispute with Servier
4M ago
CLLS
Cautious Hold Rating for Cellectis SA Amid Key Clinical and Financial Milestones
PremiumRatingsCautious Hold Rating for Cellectis SA Amid Key Clinical and Financial Milestones
6M ago
CLLS
Cellectis reports Q3 adjusted EPS 2c vs (22c) last year
Premium
The Fly
Cellectis reports Q3 adjusted EPS 2c vs (22c) last year
6M ago
CLLS
CMVLF Upcoming Earnings Report: What to Expect?
Premium
Pre-Earnings
CMVLF Upcoming Earnings Report: What to Expect?
6M ago
Cellectis to present development update for eti-cel at ASH 2025
PremiumThe Fly
Cellectis to present development update for eti-cel at ASH 2025
6M ago
CLLS
Cellectis price target raised to $4 from $3 at Wells Fargo
PremiumThe Fly
Cellectis price target raised to $4 from $3 at Wells Fargo
6M ago
CLLS
Cellectis price target raised to $8 from $4 at Barclays
PremiumThe Fly
Cellectis price target raised to $8 from $4 at Barclays
6M ago
CLLS
Cellectis SA’s Promising Study on UCART20x22 for B-Cell Non-Hodgkin Lymphoma
PremiumCompany Announcements
Cellectis SA’s Promising Study on UCART20x22 for B-Cell Non-Hodgkin Lymphoma
8M ago
CMVLF
Cellectis SA: Hold Rating Amid Upcoming Data Presentations and Financial Considerations
PremiumRatingsCellectis SA: Hold Rating Amid Upcoming Data Presentations and Financial Considerations
9M ago
CLLS
Cellectis S.A. Advances UCART123 Clinical Study in AML Treatment
Premium
Company Announcements
Cellectis S.A. Advances UCART123 Clinical Study in AML Treatment
9M ago
CLLS
Cellectis Reports Q2 2025 Results and Strategic Updates
Premium
Company Announcements
Cellectis Reports Q2 2025 Results and Strategic Updates
9M ago
CMVLF Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-Earnings
CMVLF Earnings Report this Week: Is It a Buy, Ahead of Earnings?
9M ago
Cellectis files $200M mixed securities shelf
PremiumThe Fly
Cellectis files $200M mixed securities shelf
10M ago
CLLS
Cautious Hold on Cellectis SA Amid Anticipated Data Releases and Strategic Developments
PremiumRatings
Cautious Hold on Cellectis SA Amid Anticipated Data Releases and Strategic Developments
12M ago
CLLS
Cellectis SA: Hold Rating Amid Stable Financials and Promising Collaborations, Yet Cautious Outlook Due to Market and Clinical Uncertainties
PremiumRatings
Cellectis SA: Hold Rating Amid Stable Financials and Promising Collaborations, Yet Cautious Outlook Due to Market and Clinical Uncertainties
12M ago
CLLS
Cellectis price target lowered to $4 from $5 at Barclays
PremiumThe FlyCellectis price target lowered to $4 from $5 at Barclays
12M ago
CLLS
Cellectis SA Reports Q1 2025 Financial Results
Premium
Company Announcements
Cellectis SA Reports Q1 2025 Financial Results
12M ago
Is CMVLF a Buy, Before Earnings?
Premium
Pre-Earnings
Is CMVLF a Buy, Before Earnings?
12M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >